Welcome to Contrave.ca

Obesity is a Chronic Disease.1 Are You Treating It as One?

Your patients may already know about CONTRAVE. Do you?

You may begin to see increased traffic in your clinic and we want to make sure you are equipped to discuss CONTRAVE.

A Dual-Component MOA2*

Non-clinical studies suggest that CONTRAVE has effects on two separate areas of the brain involved in the regulation of food intake.2† Find out what they are.

See MOA & Pharmacology

Clinical Data2

Phase 3 studies assessed weight change in patients with and without diabetes, weight change in conjunction with intensive BMOD counselling, as well as CV and metabolic parameters. Have you seen all of the clinical data?

See Clinical Data

All CONTRAVE Patients Can Access Their First Free Month of CONTRAVE and the CONTRAVE Support Program

FREE CONTRAVE for the first month
For pick-up at any retail pharmacy

More than 6,000 patients have enrolled on ExperienceContrave.ca and redeemed their free first month’s supply since 2021.3

  • Financial assistance
  • One-on-one coaching
  • Education and motivational content

Support For Your CONTRAVE Patients, Every Step of the Way

This short video is a great way to introduce your patients to the services offered by the CONTRAVE Support Program


Find out about ExperienceContrave.ca — one single gateway for easy patient self-enrollment!

Explore ExperienceContrave.ca

BMOD: behavioural modification; CV: cardiovascular.
*Clinical significance is unknown.
†The exact neurochemical effects of CONTRAVE leading to weight loss are not fully understood.


  1. Wharton S et al. Obesity in adults: a clinical practice guidelines. CMAJ 2020;192:E875-91.
  2. CONTRAVE Product Monograph. Bausch Health Canada, March 2, 2022.
  3. Data on File. CSP. Bausch Health, Canada Inc.

Safety Information1

Indications and Clinical use:

CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:

  • ≥30 kg/m2 (obese) or
  • ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia). The effect on cardiovascular morbidity and mortality has not been established.

The safety and effectiveness in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
Geriatrics (≥65 years of age): Use with caution.
Pediatrics (<18 years of age): Not indicated.


  • Uncontrolled hypertension
  • Current seizure disorder or a history of seizures
  • Use of other bupropion hydrochloride-containing products
  • Current or prior diagnosis of bulimia or anorexia nervosa
  • Chronic opioid or opiate agonist or partial agonists use, or acute opiate withdrawal
  • Patients undergoing an abrupt discontinuation of alcohol, benzodiazepines or other sedatives and antiepileptic drugs
  • Concomitant administration of monoamine oxidase inhibitors (MAOI)
  • Concomitant administration of the antipsychotic thioridazine
  • Pregnancy
  • Severe hepatic impairment
  • End-stage renal failure
  • Do not use in combination with tamoxifen

Most Serious Warnings and Precautions:

  • Potential association with behavioural and emotional changes, including self-harm: Bupropion, a component of CONTRAVE, is used for the treatment of depression. There is an increased risk of self-harm, harm to others, suicidal thinking and behaviour with antidepressant use. Closely monitor all patients for emergence of depression, agitation-type and/or suicidal thoughts and behaviours
  • Seizures: In order to minimize the risk of seizures the maximum recommended daily dose should not be exceeded
  • Serious drug interactions: Serious drug interactions with CONTRAVE include concomitant medicines that contain bupropion hydrochloride (e.g., WELLBUTRIN® XL, WELLBUTRIN® SR, and ZYBAN®), MAOI, and medicines that contain thioridazine

Relevant Warnings and Precautions:

  • Unmasking of Brugada syndrome
  • Interference with the action of opioid-containing drug products, vulnerability to opioid overdose, and precipitated opioid withdrawal
  • Increase in blood pressure and heart rate; not for use in patients with uncontrolled hypertension and caution in patients with controlled hypertension
  • Dependence/tolerance
  • Caution about driving and operating machinery
  • Contains lactose
  • Risk of hypoglycemia in patients with type 2 diabetes on antidiabetic therapy
  • Tamoxifen and other drugs metabolized By CYP2D6 may have reduced efficacy
  • Monitor patients with mild-to-moderate hepatic impairment or moderate-to-severe renal impairment for adverse effects that could indicate high drug or metabolite levels; dose adjustments required
  • Hepatotoxicity; discontinue in the event of symptoms and/or signs of acute hepatitis
  • Anaphylactic and hypersensitivity reactions
  • Development of cutaneous lupus erythematosus or exacerbation of systemic lupus erythematosus
  • Serotonin toxicity, also known as serotonin syndrome
  • Angle-closure glaucoma
  • Activation of mania and hallucinations
  • Not recommended in nursing mothers

For More Information:

Please consult the product monograph for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The product monograph is also available by calling 1-800-361-4261.


  1. CONTRAVE Product Monograph. Bausch Health Canada, March 2, 2022.

You are now leaving this website. Do you wish to continue?